viewValiRx PLC

ValiRx readying itself for VAL301 clinical trials

ValiRx has brought in a contract research organisation that will help it take VAL301 into the clinic

woman with abdominal pain
Aptus will help design a phase I/II study for VAL301

ValiRx Plc (LON:VAL) shares rose on Thursday following news the firm has teamed up with UK-based clinical contract research organisation Aptus to help prepare the clinical development plan for its VAL301 endometriosis treatment.

VAL301 is a reformulation of ValiRx’s flagship VAL201 anti-cancer drug that is currently in late-stage pre-clinical development.

READ: ValiRx secures US patent for VAL201

Aptus has been brought in to help bring VAL301 nearer to clinical studies, and part of its remit will be to help with the design of a phase I/II trial.

“Our agreement with Aptus represents an important stage in preparing the VAL301 compound for clinical study,” said chief executive Satu Vainikka.

“I look forward to VAL301's future development and its potential to benefit women who suffer from this extremely painful condition.”

Aptus CEO Steve McConchie added: “We look forward to exploring some innovative opportunities with the team in order to optimise the programme delivery timelines and progress this important potential treatment rapidly to patients.”

In afternoon trading, ValiRx shares were 2.9% higher at 0.18p.

 -- Adds share price --

Quick facts: ValiRx PLC

Price: 7.75 GBX

Market: AIM
Market Cap: £1.39 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...



Commercial discussions for ValiRx's lead cancer drug progressing 'rapidly'

George Morris, chief operations officer of ValiRx Plc (LON:VAL), tells Proactive's Andrew Scott commercial discussions to take their lead drug VAL 401 into a Phase III trial are progressing rapidly. He says by nature they're detailed and complex but he hopes they'll be completed shortly...

on 6/9/18

2 min read